Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial

Eur J Cancer. 2000 Sep:36 Suppl 4:S86-7. doi: 10.1016/s0959-8049(00)00240-9.

Abstract

Exemestane is an aromatase inactivator. 769 Postmenopausal women with advanced breast cancer who had failed on tamoxifen were randomised to exemestane or megoestrol acetate in this double-blind trial. Objective response rate was similar between treatments. Median time to progression, time to treatment failure and overall survival was significantly longer with exemestane. Drug-related withdrawals and drug-related deaths were more common with megoestrol acetate.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androstadienes / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Double-Blind Method
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Humans
  • Megestrol Acetate / therapeutic use*
  • Postmenopause*
  • Survival Analysis
  • Tamoxifen / therapeutic use*
  • Treatment Failure

Substances

  • Androstadienes
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Tamoxifen
  • exemestane
  • Megestrol Acetate